No abstract available.
Diagnosis* ; Prostate* ; Prostatic Neoplasms* ; Ultrasonography*

No abstract available.
Lithotripsy* ; Shock* ; Ureter* ; Ureteroscopy*

No abstract available.

Wilms` tumor originates from pleuripotential mesenchymal cells of the metanephrogenic blastema. Improvement on surgery and anesthesia, addition of radiation therapy and chemotherapy have produced remarkable improvements in survival over the past several decades. Twenty-eight patients with histologically confirmed diagnoses of Wilms` tumor were treated from l972 through l987 at the University Hospital, Keimyung University School of Medicine. l. Two year survival rate according to tumor stage was 80% in stage I, 7516 in stage II , 57.1% in stage III and 25% in stage IV and the overall 2 year survival rate was 57.1 1K . 2. Two year survival rate according to age was 75% in below l year, 50% between l to 2 years old, 54.5% between 2 to 6 years old and 60% above 6 years old. However, there seems to be no close relationship between age and prognosis. 3. Two year survival rate before 1978 was 45.5% and after 1978 was 45.5% and after 1978 it was 61.6% 4. There was 76.0 percent overall survival for those with negative nodes versus 33.3 per cent survival for those with positive nodes. 5. Two year survival rates of FH(Favorable Histology) and UH(Unfavorable Histology) were 68.2% and 16.7% respectively. There seems to be close relationship between FH and UH.
Anesthesia ; Child ; Child, Preschool ; Diagnosis ; Drug Therapy ; Humans ; Prognosis* ; Survival Rate

In adenomatous polyposis coli there are many colonic and extracolonic manifestations, and various combinations of these induce different clinical presentations and syndromes. We experienced a unique case of adenomatous polyposis of the large intestine and stomach in a 39-year-old man. In the colon, small cell neuroendocrine carcinoma rather than adenocarcinoma had developed, which did not contain adenomatous or carcinomatous foci. The adenomatous polyps in the colon were all small and sessile with no cancerous or precancerous change two years after the resection of the symptomatic gastric adenomas, even though the gastric adenomas were larger and showed dysplastic change. We think this case is another variant of adenomatous polyposis syndrome.
Adenocarcinoma ; Adenoma

No abstract available.
Urinary Bladder Neoplasms* ; Urinary Bladder*

Patients with advanced urothelial tumors that relapse or persist following conventional therapy have poor prognosis. Management of the patients with recurrent local or disseminated urothelial tumors presents a difficult clinical problems. In 1985 Sternberg et al reported 71% of significant tumor regression and 50% of complete clinical remission with M-VAC (methotrexate, vinblastine, doxorubicin and Cisplatin) combination chemotherapy for treatment of advanced urothelial transitional cell carcinomas. Herein, we have experienced 13 cases of M-VAC combination chemotherapy in advanced urothelial tumors. Complete and partial remission was in achieved 46.2 per cent of the patients clinically, while 15.4 percent had a minor response and 38.4 per cent had progression with median survivals of 11.5, 8.5 and 7.4 months. Toxicity was significant. 15.4 per cent of the patients having experienced nadir sepsis, 30.8 per cent mucositis and 7.6 per cent cardiac toxicity. Median cycle length varied from 31.6 to 41.7 days for the first and 5th cycle respectively. This regimen has been efficacious in selected patients with advanced urothelial tumors.
Carcinoma, Transitional Cell ; Doxorubicin* ; Drug Therapy, Combination ; Humans ; Mucositis ; Prognosis ; Recurrence ; Sepsis ; Vinblastine*

No abstract available.
Diagnosis* ; Ultrasonography* ; Varicocele*

No abstract available.
Hernia*

BACKGROUND: The survival rate of children with neuroblastoma has been improved over 20 years, excluding the metastatic disease, in which it does not exceed 20% so far. New treatment modalities have been developed to improve the outcome in metastatic disease. Preoperative chemotherapy reduce the size, the vascularity and the adhesiveness, so increase the resectability of the primary tumor. This retrospective clinical study was designed to review the survival rate in neuroblastoma and to analyze the effect of preoperative chemotherapy in the view point of neoadjuvant therapy on long-term survival in advanced disease. METHODS: One hundred and thirty-four cases were reviewed from 135 patients with neuroblastoma registered at the Department of Pediatrics in Seoul National University Children's Hospital from January, 1985 till December, 1995. The survival rate was reviewed according to the stage. The age, sex of the patients, the stage, anatomical site of the tumor, the level of serum ferritin and neuron-specific enolase were analyzed for the risk factors on survival. RESULTS: Ranges of age at diagnosis were from 1 month to 166 months with the median of 39 months. Five year survival rates and five year disease-free survival rates were 100%, 100% in stage 1(n=5), 90.9%, 90.9% in stage 2(n=13), 43.4%, 40.6% in stage 3(n=19), 27.1%, 19.8% in stage 4(n=95) and 100%, 100% in stage 4S(n=2), respectively. In stage 3, five year survival rate was 52.5% in group receiving neoadjuvant chemotherapy, 28.6% in control group(P=0.02). Five year disease-free survival rate was also noted as 48.6%, 28.6% in each group(P=0.02). In stage 4, five year and ten year survival rates were 27.6%, 23.6% in group receiving neoadjuvant chemotherapy, 26.9%, 0% in control group(P=0.02). Five year and ten year disease-free survival rates were 14.3%, 14.3% in group receiving neoadjuvant chemotherapy, 20%, 0% in control group (P=0.11). In univariate analysis, the age, the stage, and the site of primary tumor appeared to affect the long-term survival. CONCLUSION: Neoadjuvant chemotherapy and delayed primary surgery contribute for advance in survival in advanced neuroblastoma via increasing the resectability of the primary tumor.
Adhesiveness ; Child ; Diagnosis ; Disease-Free Survival ; Drug Therapy* ; Ferritins ; Humans ; Neoadjuvant Therapy ; Neuroblastoma ; Pediatrics ; Phosphopyruvate Hydratase ; Retrospective Studies ; Risk Factors ; Seoul ; Survival Rate